EQ vs ERAS

Equillium, Inc. vs Erasca, Inc. — Valuation Comparison 2026

EQ

Biotechnology
Equillium, Inc.
Quality
6.4
out of 10
Value Trap
24
SAFE
Price
$2.84
Last close
Models
9/13
Active
VS

ERAS

Biotechnology
Erasca, Inc.
Quality
4.2
out of 10
Value Trap
24
SAFE
Price
$12.20
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType EQ Fair ValueEQ Upside ERAS Fair ValueERAS Upside
Bayesian DCF Intrinsic $1.29 -54.6% $3.70 -69.7%
Earnings Power Value Intrinsic $9.40 -56.3%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.05 -97.4% $0.94 -90.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EQ vs ERAS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EQ vs ERAS — Which Stock Is More Undervalued?

EQ scores higher with a 6.4/10 quality rating vs ERAS's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Equillium, Inc. (EQ) and Erasca, Inc. (ERAS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EQ currently trades at $2.84 with a QOC of 6.4/10, while ERAS trades at $12.20 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).